U.S. Markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
29.06+0.58 (+2.04%)
At close: 4:00PM EDT

29.06 0.00 (0.00%)
After hours: 4:35PM EDT

People also watch
GNVCIMMUCRISBCRXIMGN
  • F
    Fghyujk Sdfghj
    Fghyujk Sdfghj
    Terry will not say the price or possible scenario.His comments about IV iplex etc are polite comments to my wife__)) Make it of what you will. Terry enjoys wide gratitude in a paid trading room.He has been very active the last few months and we are talking big money.Quite a few took the INSM buy "with both fists" at $11.9.... .sell at $ + 29+ just over a month trade.-=-==-=-
    Karen, I will politely ask board screamer kinkey-boots to please stop with the spam and ridicule of posters elsewhere. They may not be as experienced or knowledgeable of Insmed but they are seeking answers. I will agree the recent spat of iplex hype is mostly wrong.What needs to be said is that iplex with the exception of the short lived approval of short stature iplex was never really trialed. From MDD to ALS to HARS the trials were exploratory.( under the guise of a Phase2a..... I wrote of this to a poster that the ROP would fail .It did and now ! Voila! ..... a new 5 year exploratory trial has been given the FDA fasttrack seal of ..CYA ... Just like arikayce got 5 years ago! - that is before the FDA mandated a 2 year delay ! and a real trial.

    A iplex Italian and US compassionate care programs (MMD ALS) resulted in little to expand iplex..Insmed trying to keep on a happy face told shareholders that they were"designing a trial for severe insulin resistance! It never happened.
    IGF-1 is similar to insulin and was shot down in the markeplace because of a hypoglycemic side effect.... sales were miniscule
    There is no 2009 iplex left with that approval hence there is no approval.

    Even if you dont have the sources that have been available ( Napo etc) all you have to do is follow the money. IV is a group of very poor investors that never accepted Iplexs failure. Everyone else moved on. If any indication had showed promise ..and none did.. I guarantee an iplex product trial and investment would have happened long ago. To think that Investment money is being cruel or not allowing Insmed etc you are foolish .......money would have had a market.
    The most promising ROP garnered 25M for all rights.If you are holding your breath for another rights deal well then Good Luck

    My call on the new low and what I think happens next is for our trading room and not for these jerks. I have suggested all avoid IV... its bad for your investment knowledge Recent threads have validated this in spades. Look at the sentiment on the board before and after the results .... better than Math!..... so maybe there is some value.
    Now @#$% @%#* #$%^
    Best!
    Terry

    ( remember arikayce "sales in France ! ))) =1 patient .... give Lewis his due. He got Goldman Sachs A takeout price will benefit guess who ? ....
  • K
    Kinky
    Kinky
    deleted from this morning
    zake1 wants to know why we have not heard from Insmed regarding this ! ! \ \ "SERIOUSLY! \ \ Re: Shire Receives FDA Fast Track Designation for SHP607 for the Prevention of Chronic Lung Disease in Extremely Premature Infants\
    ITS NOT INSMEDS \ \ \ ITS SHIRES ! DUHHHHHHHhhhh
  • E
    Endo
    Endo
    Kinkys taunts aside Why would this board be hyping iplex and Shire?This is not relevant to shareholders of INSM
    Why would Insmed spend money when they have a proven technology in Arikayce
  • l
    linda
    linda
    Endo Item #!
    The type of filing will tell us a lot. If the FDA response is hidden in a PR or 8k and the NDA is regular form there are questions about the dropout rate. Insmed has already doubled the price of the drug which tells you they known the market shrunk with the results (failed secondary). If there is an accelerated review the label may be more favorable
  • K
    Kinky
    Kinky
    ALL FALSE ! ZAKE! is lying \ There is a whole lot more here than I remember...first of all..these are some of the issues Iplex was approved for, and found safe...think of all the people that suffered because of this
    1.54 “Named Patient Indications” means myotonic muscular dystrophy, HIV related Adipose Redistribution Syndrome (HARS), retinopathy of prematurity, recovery from burns and trauma, and recovery from hip fracture.
  • l
    linda
    linda
    my post from yesterday on filing protocol was deleted
  • l
    linda
    linda
    Anyone commenting about possible revenues in Q1 2018 immediately show they do not have any understanding of the issues at hand.
  • K
    Kinky
    Kinky
    John Dsouza \ " as they provide further updates on data and recent submission" FALSE\ GO BACK TO INVESTOR VILLAGE
    THERE WAS NO SUBMISSION
  • J
    Joe Blow
    Joe Blow
    SEC Insider SHAROKY MELVIN MD sold 50,000 shares
  • A
    Anonymous
    Anonymous

    MDNA.TO (MC C$36 M) (Cash C$20 M) Hot Cancer Play with important Results in Q1 that could lead to FDA approval =1500-2000% UPSIDE Potential ! RALLYYYYYYYYYYY

    Brutally cheap and completely unknown canadian biotech stock with minimum 10 bagger potential . Positive Phase 2 results in recurrent glioblastoma which expected in Q1 2018 could lead to accelerated approval which would be a HUGE MAJOR milestones for this undiscovered low float stock . This company has brutally low valuation of only $36 million and most of that in cash $20 million which is enough untill Q1 2019 . This stock at $1.50 is a lifetime opportunity and we could see $15-20 easily on Positive 2 results and FDA approval .GL

    Medicenna Therapeutics (MDNA.TO)

    Market Cap C$36 Million
    Cash : C$ 20 Million << enough untill Q1 2019
    Price : $1.50

    Shares Out: 24.3 Million ( 15.5 Million shares held by Insider alone )

    Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
    https://smallcappower.com/videos/companies-to-watch/medicenna-therapeutics-tsxv-mdna/

    New Presentation
    http://s21.q4cdn.com/710416940/files/doc_presentations/2017/Medicenna-Corporate-Presentation-Q3-2017.pdf

    Fact Sheet
    http://s21.q4cdn.com/710416940/files/doc_downloads/fact_sheet/Medicenna-FS-Q1-2017-v2.pdf

    Insider Ownership :

    Aries Biologics, Inc. 5 500 000
    Rosemina Merchant 5 050 000
    Fahar Merchant 5 050 000
    Elizabeth Williams 5 300
    Chandrakant J. Panchal, PhD 1 000
    Trevor P. Wong-Chor 714

    Medicenna Therapeutics (TSXV: MDNA) CEO: Our Drug Has Potential for Phase 2 Approval
    Medicenna Therapeutics Corp. (CVE:MDNA) President & CEO Fahar Merchant said the Company received a large grant from the state of Texas.
    smallcappower.com
  • K
    Kinky
    Kinky
    Why Investor village is dangerous.zake asks the "Piano master" to opine on something he then makes up a story and longtime stupid "JAD9000" chimes in JAD9000 . I agree with prior posts that we should be selling in the US by Q1, 2018."
    It is important to realize that all these posters are simply making up stories without substance.Laugh at the $50 dollars soon but the timeline in anyones investment should be important and simply put these people are lying STAY THERE!
  • J
    John Dsouza
    John Dsouza
    This will bounce between $28 and $31 for a few weeks and then will surpass mid 30s as they provide further updates on data and recent submission. I suspect when we get Fast Track news it'll spike to mid 30s plus. Nothing wrong in taking profits from trading shares but most people are probably not touching their core shares!
  • m
    mark
    mark

    http://www.smarteranalyst.com/2017/09/11/cowen-sees-high-80-probability-fda-approval-insmed-incorporateds-insm-ntm-drug/

    Cowen Sees High 80% Probability of FDA Approval for Insmed Incorporated’s (INSM) NTM Drug
    Insmed's lead asset ALIS poses compelling prospects for commercial success in the U.S., says top analyst.
    www.smarteranalyst.com
  • S
    Sport
    Sport
    What is going on? Up any news?
  • J
    Jay
    Jay
    It seems that shorting is starting now and we will see how low it will go. Any comment?
  • l
    linda
    linda
    "Jay" Here are some "facts" .The clinical trial follow up will take 2 years but the 6 month data is the FDA endpoint. Insmed plans to file.29% is a good number of patients to be CURED. Nothing else comes close.Your 71% is misleading since 71% of NTM patients will not use the drug. Arikayce will be for refractory patients only.{meaning only who fail antibiotics completely)The only one misleading is you because it is clear you do not understand Arikayce
  • D
    Dan
    Dan
    Seems like it is headed lower. A few more days than I thought. Profit taking soon when it starts below $24
  • L
    L
    L
    Glad I went back to the short side yesterday!! Ouch for those that are long.
  • J
    Joe West
    Joe West
    How long to file review approval and Launch? Serious relies only
  • F
    Fghyujk Sdfghj
    Fghyujk Sdfghj
    # Terry just prognosticated the INSM low.#also sent a nice note last night I asked if I can repost #lunchtime #go away Jose#